{"entity":{"id":"cimavax-egf","kind":"drug","name":"CIMAvax-EGF","aka":["CIMAvax","EGF vaccine","rhEGF-rP64K conjugate vaccine"],"tldr":"CIMAvax-EGF is a Cuban vaccine for advanced non-small cell lung cancer, given after chemotherapy so the body blocks a growth signal the tumour uses. Cuba registered it in 2008. In its phase III trial the survival gain was not significant by the standard test, but was by a weighted test and among patients given at least four doses. It is not approved in the United States or the European Union.","summary":"CIMAvax-EGF is made at the Centro de Inmunología Molecular in Havana, which holds its registration. It is recombinant human epidermal growth factor chemically conjugated to the recombinant carrier protein rP64K and emulsified with the adjuvant Montanide ISA 51 VG; the vaccine is intended to induce antibodies against the patient's own EGF that block its binding to the EGF receptor. Cuba's regulator CECMED lists it under registration number B-08-063-L03, entered on 12 June 2008, for patients with advanced (stage IIIB or IV) non-small cell lung cancer.\n\nIn the Cuban phase III trial, 405 patients with stage IIIB or IV disease were randomised four to six weeks after first-line chemotherapy to the vaccine or to best supportive care. Median survival was 10.83 months with the vaccine and 8.86 months without (hazard ratio 0.82, P = 0.100 by the standard log-rank test; P = 0.04 by a weighted log-rank test applied after the hazards proved non-proportional). Among patients who received at least four doses it was 12.43 against 9.43 months (hazard ratio 0.77, P = 0.036), and 14.66 months in vaccinated patients with a high EGF concentration at baseline. The trial compared the vaccine with supportive care, not with a placebo or with the maintenance and immunotherapy treatments now standard elsewhere. A phase 1/2 trial sponsored by Roswell Park in the United States combines it with nivolumab or pembrolizumab (NCT02955290).","status":"established","asOf":"2026-11-18","links":[{"label":"CECMED: registration entry and summary of product characteristics for CIMAvax-EGF (in Spanish)","url":"https://www.cecmed.cu/registro/rcp/biologicos/cimavaxr-egf-conjugado-quimico-factor-crecimiento-epidermico-humano"},{"label":"Rodriguez et al., phase III trial of CIMAvax-EGF in advanced NSCLC (Clin Cancer Res 2016)","url":"https://doi.org/10.1158/1078-0432.CCR-15-0855"},{"label":"ClinicalTrials.gov: NCT02955290, CIMAvax with anti-PD-1 therapy (Roswell Park)","url":"https://clinicaltrials.gov/study/NCT02955290"}],"tags":["cuba","cancer-vaccine"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cimab"],"institutions":["cecmed"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016"],"journals":[],"dependsOn":[],"notes":["Not approved by the FDA or the EMA. Registrations in other countries are reported in the press and were not read from a regulator's own page, so none is listed."],"brand":"CIMAvax-EGF","modality":"Therapeutic cancer vaccine: recombinant human EGF conjugated to a carrier protein, with Montanide ISA 51 adjuvant, intramuscular","mechanism":"Makes the body produce antibodies against its own epidermal growth factor (EGF), lowering EGF in the blood so that less of it reaches the EGF receptor on tumour cells. It does not target the tumour cell directly.","approvals":[{"region":"Cuba (CECMED)","year":2008,"indication":"Advanced (stage IIIB or IV) non-small cell lung cancer","note":"Registration number B-08-063-L03, entered 12 June 2008; holder Centro de Inmunología Molecular. CECMED summary of product characteristics: \"CIMAvax®-EGF está indicado en pacientes con cáncer de pulmón de células no pequeñas, en estadios avanzados (IIIb / IV).\" https://www.cecmed.cu/registro/rcp/biologicos/cimavaxr-egf-conjugado-quimico-factor-crecimiento-epidermico-humano"}],"mechanismSteps":[],"dosing":{"route":"Intramuscular","schedule":"One dose of cyclophosphamide 200 mg/m2, then three days later four doses of the vaccine 14 days apart, then monthly; each dose is four injections at different sites (CECMED summary of product characteristics, text of 6 October 2017)"},"toxicity":[{"event":"Injection-site reactions; flushing, chills, tremor, headache, nausea, vomiting, fever","note":"The CECMED summary describes most adverse events as mild or moderate across more than 1,000 patients in 13 trials, and says severe systemic reactions can occur and respond to antihistamines, antipyretics and analgesics."}],"access":[],"regulatoryEvents":[{"date":"2008-06-12","type":"approval","region":"Cuba","note":"CECMED registration B-08-063-L03 entered for advanced non-small cell lung cancer (date of inscription in the summary of product characteristics)","source":"https://www.cecmed.cu/registro/rcp/biologicos/cimavaxr-egf-conjugado-quimico-factor-crecimiento-epidermico-humano"}]},"route":"/drugs/cimavax-egf/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"cimab","kind":"company","name":"CIMAB","route":"/companies/cimab/"}],"institution":[{"id":"cecmed","kind":"institution","name":"Center for State Control of Medicines, Equipment and Medical Devices (CECMED)","route":"/institutions/cecmed/"}],"paper":[{"id":"paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016","kind":"paper","name":"CIMAvax-EGF as switch maintenance in advanced non-small cell lung cancer: the Cuban phase III trial","route":"/key-papers/paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016/"}]}}